(MedPage Today) — Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) compared with docetaxel, the phase III KRYSTAL…
Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116919
Author :
Publish date : 2025-08-08 20:14:00
Copyright for syndicated content belongs to the linked Source.
